– Half of participants are now enrolled in study evaluating ecopipam (EBS-101) as a potential first-in-class treatment for pediatric patients with Tourette Syndrome – Chicago – September 1, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous … Read more
– Biopharmaceutical company advancing clinical research evaluating novel treatment for Tourette syndrome and childhood-onset fluency disorder – Farmington, Connecticut & Chicago, Illinois – June 3, 2020 – Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form … Read more
(CHICAGO, August 28, 2019) – Emalex Biosciences, Inc. (Emalex), a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, announced today that it has received Fast Track designation for its investigational product, ecopipam, from the U.S. Food and Drug Administration (FDA) for … Read more
CHICAGO (August 14, 2019) – Emalex Biosciences, Inc., a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, announced today that the first patient was recently enrolled in the company’s international Phase 2b study to evaluate the efficacy and safety of ecopipam … Read more
CHICAGO, IL, August 6, 2019 — Emalex Biosciences Inc., a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, today announced the appointment of Atul Mahableshwarkar, MD, as Senior Vice President of Drug Development. In this capacity, Dr. Mahableshwarkar will provide leadership … Read more